Market Place
Sourcing Support
Ultimovacs ASA Reports Q3 2024 Results & Business Update
06 Nov 2024 //
GLOBENEWSWIRE
Ultimovacs ASA: Invitation to Q3 2024 results webcast presentation
31 Oct 2024 //
GLOBENEWSWIRE
Ultimovacs Publishes Phase II FOCUS Trial Results on medRxiv
25 Oct 2024 //
GLOBENEWSWIRE
Ultimovacs Halts Patient Recruitment In LUNGVAC Trial For Lung Cancer
11 Sep 2024 //
GLOBENEWSWIRE
Ultimovacs Updates On UV1 Phase II NIPU Trial At ESMO 2024
08 Sep 2024 //
GLOBENEWSWIRE
Ultimovacs ASA: Invitation to second quarter 2024 results webcast presentation
15 Aug 2024 //
GLOBENEWSWIRE
Ultimovacs Announces FOCUS Phase II Trial Results For UV1
05 Aug 2024 //
GLOBENEWSWIRE
Ultimovacs Cancer Vaccine Fails Third Trial
05 Aug 2024 //
FIERCE BIOTECH
Ultimovacs To Present NIPU Trial Update At ESMO Congress 2024
01 Aug 2024 //
GLOBENEWSWIRE
Ultimovacs Poster On UV1 Cancer Vaccine At 2024 ASCO Annual Meeting
01 Jun 2024 //
GLOBENEWSWIRE
Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation
30 Apr 2024 //
GLOBENEWSWIRE
Ultimovacs lays off 40% in wake of cancer vaccine`s phase 2 fail
17 Apr 2024 //
FIERCE BIOTECH
Ultimovacs Adjusts Operations to Advance UV1 Vaccine Phase II Program
16 Apr 2024 //
GLOBENEWSWIRE
Ultimovacs to Present Poster at the AACR Annual Meeting 2024
04 Apr 2024 //
GLOBENEWSWIRE
Ultimovacs ASA: Annual Report 2023
21 Mar 2024 //
GLOBENEWSWIRE
Ultimovacs Receives EMA Orphan Drug Designation for UV1 Cancer Vaccine
19 Feb 2024 //
GLOBENEWSWIRE
Ultimovacs ASA: Invitation to fourth quarter 2023 results webcast presentation
08 Feb 2024 //
GLOBENEWSWIRE
Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine
05 Feb 2024 //
GLOBENEWSWIRE
Ultimovacs Announces Completion of Patient Enrollment in Study to INITIUM
02 Nov 2023 //
GLOBENEWSWIRE
Ultimovacs ASA: Invitation to third quarter 2023 results webcast presentation
02 Nov 2023 //
GLOBENEWSWIRE
Ultimovacs links BMS-cancer vaccine combo to improved survival
18 Oct 2023 //
FIERCE BIOTECH
Ultimovacs Receives FDA Orphan Drug Designation for the UV1 Cancer Vaccine
09 Oct 2023 //
GLOBENEWSWIRE
Ultimovacs ASA: Invitation to second quarter 2023 results webcast presentation
15 Aug 2023 //
GLOBENEWSWIRE
Ultimovacs Announces Publication in Clinical Cancer Research of the UV1-103
28 Jun 2023 //
GLOBENEWSWIRE
Ultimovacs issues positive long-term survival results for its cancer vaccine
19 Jun 2023 //
CLINICAL TRIALS ARENA
Ultimovacs ASA: Invitation to 1Q 2023 results webcast presentation
03 May 2023 //
GLOBENEWSWIRE
Ultimovacs Receives Intention to Grant Notice on European Patent on UV1
13 Apr 2023 //
GLOBENEWSWIRE
